Health tech firm Hyperfine's prelim Q3 revenue misses estimates

Reuters
Oct 16, 2025
Health tech firm <a href="https://laohu8.com/S/HYPR">Hyperfine</a>'s prelim Q3 revenue misses estimates

Overview

  • Hyperfine prelim Q3 2025 revenue grows 27% sequentially but misses analyst expectations

  • Company reports 27% decline in cash burn from Q2 2025

  • Strong demand for next-gen Swoop system drives revenue growth

Outlook

  • Company did not provide specific guidance for future quarters or full-year

Result Drivers

  • NEXT-GEN SWOOP DEMAND - Strong market excitement and demand for next-gen Swoop system and Optive AI software drove revenue growth

  • DEVICE SELLING PRICE - Effective average device selling price increased by 36% sequentially, reflecting market acceptance of next-gen Swoop system

  • CASH BURN REDUCTION - Cash burn decreased by 27% sequentially, indicating improved financial management

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Miss

$3.40 mln

$3.50 mln (3 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Hyperfine Inc is $1.40, about 46.4% below its October 14 closing price of $2.05

Press Release: ID:nBw9nhzbha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10